Europe’s pharma trade with the US remains critical despite tariff turmoil

Europe’s pharma trade with the US is under threat as tariffs rise, impacting key players like Pfizer. The US government’s Most Favored Nation policy and recent tariff hikes could disrupt a market where the US holds a 40% share of global drug development.

Despite exploring Asian markets, experts warn that Europe can't easily replace the innovation and profitability of the US. The EU's recent free trade agreement with India may help, but US markets remain crucial for European pharma's success.